Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a gentle brain zap make counseling more effective for cannabis users?

NCT ID NCT07787572

Disease control Sponsor: The Mind Research Network Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 26, 2026 · Last updated Aug 28, 2026 · Updated 2 times

Summary

This trial explores whether adding a gentle brain stimulation technique called transcranial alternating current stimulation (tACS) to a brief counseling session can help adults with cannabis use disorder. The counseling, known as motivational interviewing, helps people talk through their reasons for changing their cannabis use. Researchers will compare active tACS to a placebo version, measuring what participants say during the session, brain activity afterward, and cannabis use over the following month. The goal is to see if this combination can strengthen the counseling's impact.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
transcranial alternating current stimulation (tACS) — a device that delivers a weak electrical current to the brain via scalp electrodes during a counseling session
What this could lead to
If it works, this could point toward a way to make brief counseling more effective for people trying to cut back on cannabis, potentially improving treatment outcomes.
What could go wrong
This is an early-stage trial with a modest number of participants, so results may not be conclusive. The stimulation is weak and short, and its effect on real-world cannabis use is uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 82 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

Aug 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

21 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * self-identification as having problematic cannabis use * age 21-65 years * SCID-5-RV module E indicating current cannabis use disorder Exclusion Criteria: * currently engaged in treatment for any substance use disorder (SUD) * receiving treatment for any SUD within the prior 30 days * history of brain injury or major neurological diagnosis, vascular/neurodegenerative disorder, or complex primary headache disorder * evidence of current psychosis * past-year substance use disorder other than cannabis, alcohol, or nicotine * positive urine drug screen for any illicit drug other than cannabis * current or recent (past-month) medically significant withdrawal * MRI/tACS contraindications, including pregnancy * impaired hearing (psychotherapy using American Sign Language is not possible within the scope of this study) * insufficient corrected visual acuity to complete the assessment instruments * unable to read/speak English fluently * unable to provide valid informed consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cannabis use disorder are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cannabis dependence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cannabis use disorder

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • The Mind Research Network

    Albuquerque, New Mexico, 87106, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.